Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/8/2013

of 2012.  Common shares used in calculating basic and diluted earnings per share were 37,133,358 for the first quarter of 2013 compared to 19,607,483 for the first quarter of 2012.

During the first quarters of 2013 and 2012, AcelRx recognized revenue of $940,000 and $329,000, respectively, resulting from reimbursement for work completed under a research grant from the U.S. Army Medical Research and Materiel Command, or USAMRMC, for development of ARX-04, a sufentanil NanoTab product candidate for the treatment of moderate-to-severe acute pain in a range of ambulatory environments.Research and development, or R&D, expenses for the quarter ended March 31, 2013 totaled $9.3 million, compared with $4.8 million for the quarter ended March 31, 2012.  The increase was primarily due to expense associated with Phase 3 clinical studies of the Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain, and Phase 2 study expenses for the single-dose sufentanil NanoTab product candidate, ARX-04.General and administrative expenses were $2.2 million for the first quarter of 2013, compared with $2.1 million for the quarter ended March 31, 2012.Other income and expense includes a $1.8 million non-cash charge in the first quarter of 2013 resulting from the liability accounting related to the warrants issued in connection with the PIPE financing completed in June 2012.  The primary determinant of this charge was an increase in stock price during the first quarter of 2013 and its resulting impact on the Black-Scholes valuation of these warrants.

As of March 31, 2013, AcelRx had cash, cash equivalents and investments of $48.2 million, compared to $59.8 million at December 31, 2012.

Review of Recent Accomplishments and Corporate Update

  • On March 5, 2013, AcelRx announced positive top-line results from the first of two pivotal Phase 3 double-blind, placebo-controlled efficacy and safety clinica
    '/>"/>

  • SOURCE AcelRx Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
    2. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
    3. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
    4. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
    5. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
    6. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
    7. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
    8. AcelRx Pharmaceuticals Provides Clinical Trial Updates
    9. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
    10. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    11. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
    (Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
    (Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
    Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
    (Date:4/24/2014)... Philadelphia, Pa. (April 24, 2014) - Contact lenses coated with ... contact lens-related infections, reports a study in Optometry ... American Academy of Optometry . The journal is published ... Wolters Kluwer Health . , Studies in animals and ... with the antimicrobial peptide melimine, according to the new research ...
    (Date:4/24/2014)... irrelevant, could offer an alternative to heart transplants for ... and her team from the Australian Regenerative Medicine Institute ... is a close relative to a cardiomyocyte, the cell ... published today in Circulation Research , Dr Furtado ... to their genetic program, and will aid in the ...
    (Date:4/24/2014)... researchers was the first in the world to discover ... of the jaw. , Ameloblastoma is an odontogenic tumour ... is most often found in the posterior of the ... in tissue deficiencies in the jaws as well as ... reduce the need for surgery and the recurrence of ...
    (Date:4/24/2014)... by a scientist at the University of York reveals ... the development of the nervous system may also play ... A research team, led by Dr Will Brackenbury, ... Biology at York, has studied how voltage-gated sodium channels ... are found in the membranes of excitable cells, such ...
    (Date:4/23/2014)... SPOKANE, Wash.Researchers at Washington State University Spokane have ... are about to nod off behind the wheel. ... steering wheel movementswhich are more variable in drowsy ... to currently available video-based driver drowsiness detection systems. ... detect when a car is drifting out of ...
    Breaking Medicine News(10 mins):Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Boring cells could hold the key to heart disease 2Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2
    ... Va., Aug. 21, 2008 The AMERIGROUP,Foundation today ... has,been honored with its "Champion for Children" award., ... Foundation,s national program,recognizing outstanding public advocacy efforts by ... well-being of children throughout our,nation., "Our goal ...
    ... & CEO of Blue Shield of California will participate ... Health, Wellness and,Prevention at the start of the Democratic ... at Boettcher Hall in the Denver Performing,Arts Complex. Mr. ... reform, and the ways in which health plans work ...
    ... 21 L.A. Care Health Plan,announced today that it ... National Committee for Quality Assurance (NCQA), an,independent, non-profit organization ... managed care plans. L.A. Care,s Accreditation,status - the highest ... of how,a health plan ensures that its members are ...
    ... Calif., Aug. 21 The Pancreatic Cancer,Action Network ... in a comprehensive way through research, patient support,community ... by the loss of NFL,Hall of Fame member ... offers its condolences to the,Upshaw family and the ...
    ... A universal vaccine effective against several strains of ... to Dr. Christine Turley of the University of Texas ... trials and clinical research at the Sealy Center for ... said that VaxInnate,s M2e universal vaccine could possibly protect ...
    ... have evolutionary distaste for bitter remedies, foods, study finds ... your child won,t take medicine and shuns broccoli at ... to respond that way. , "Kids reject the bad ... system is designed to reject that taste, because many ...
    Cached Medicine News:Health News:Texas State Rep. Sylvester Turner Honored as 'Champion for Children' by The AMERIGROUP Foundation 2Health News:Blue Shield of California CEO to Speak at Democratic Convention Host Committee's Health Roundtable in Denver 2Health News:NCQA Awards L.A. Care Health Plan Its Highest Accreditation Status of Excellent 2Health News:The Pancreatic Cancer Action Network is Saddened by the Death of NFL Hall of Fame Member Gene Upshaw 2Health News:Spoonful of Sugar Really Might Help Medicine Go Down 2Health News:Spoonful of Sugar Really Might Help Medicine Go Down 3